CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this release are "forward-looking statements"
under the securities laws. Words such as, but not limited to, "believe,"
"expect," "anticipate," "estimate," "intend," "plan," "targets," "likely,"
"will," "would," and "could," and similar expressions or words, identify
forward- looking statements. Forward-looking statements are based upon
current expectations that involve risks, changes in circumstances,
assumptions and uncertainties. Vanda is at an early stage of development
and may not ever have any products that generate significant revenue.
Important factors that could cause actual results to differ materially from
those reflected in the company's forward-looking statements include, among
others: delays in the completion of Vanda's clinical trials; a failure of
Vanda's product candidates to be demonstrably safe and effective; Vanda's
failure to obtain regulatory approval for its products or to comply with
ongoing regulatory requirements; a lack of acceptance of Vanda's product
candidates in the marketplace, or a failure to become or remain profitable;
Vanda's inability to obtain the capital necessary to fund its research and
development activities; Vanda's failure to identify or obtain rights to new
product candidates; Vanda's failure to develop or obtain sales, marketing
and distribution resources and expertise or to otherwise manage its growth;
a loss of any of Vanda's key scientists or management personnel; losses
incurred from product liability claims made against Vanda; a loss of rights
to develop and commercialize Vanda's products under its license and
sublicense agreements and other factors that are described in the "Risk
Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form
10-Q for the quarter ended June 30, 2008 (File No. 000-51863). In addition
to the risks described above and in Part II, Item 1A of Vanda's quarterly
report on F
|SOURCE Vanda Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved